静止期癌细胞：克服免疫疗法耐药性的治疗靶点？
Quiescent cancer cells: Therapeutic targets to overcome immunotherapy resistance?
机构信息
Department of Medicine, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, 5117 Centre Avenue, 1.46e, Pittsburgh, PA 15213, USA.
Departments of Pathology and Oncology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA.
出版信息
Med. 2022 Jun 10;3(6):358-360. doi: 10.1016/j.medj.2022.05.013.
Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor clinical outcomes. Chemoimmunotherapy improves outcomes in high-risk, early-stage disease, but not all patients benefit. Baldominos and colleagues drill down into early TNBC sub-microenvironments using single-cell technologies, characterizing quiescent cancer cell niches that may drive immunotherapy resistance and disease relapse.
三阴性乳腺癌（TNBC）是一种异质性疾病，临床预后较差。化疗免疫治疗可改善高危早期疾病的预后，但并非所有患者均从中获益。Baldominos 及其同事使用单细胞技术深入研究早期 TNBC 的亚微环境，对可能导致免疫治疗耐药和疾病复发的静止癌细胞生态位进行了特征描述。
Zotero 插件